US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalaris Therapeutics Inc.

6.99

+0.29004.33%

Post-market: 6.990.00000.00%16:05 EDT

Volume:19.20K

Turnover:135.04K

Market Cap:130.73M

PE:-0.67

High:7.31

Open:6.52

Low:6.52

Close:6.70

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Kalaris Therapeutics Inc.

Exchange:

NASDAQ

Establishment Date:

2019

Employees:

14

Office Location:

628 Middlefield Road,Palo Alto,California,United States

Website:

http://www.allovir.com

Zip Code:

94301

Phone:

- -

Fax:

- -

Introduction:

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Directors

Name

Position

David Hallal

Chief Executive Officer and Director

Vikas Sinha

President, Chief Financial Officer and Director

Ansbert Gadicke

Director

Diana Brainard

Director

Jeffrey S. Bornstein

Director

John Wilson

Director

Juan Vera

Director

Malcolm Brenner

Director

Morana Jovan Embiricos

Director

Shareholders

Name

Position

David Hallal

Chief Executive Officer and Director

Vikas Sinha

President, Chief Financial Officer and Director

Agustin Melian

Chief Medical Officer

Ann Leen

Chief Scientific Officer

Brett Hagen

Chief Accounting Officer

Edward Miller

General Counsel

Ercem Atillasoy

Chief Regulatory and Safety Officer

Jeroen van Beek

Chief Commercial Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/KLRS/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":6.99,"timestamp":1744920000000,"preClose":6.7,"halted":0,"volume":19203,"hourTrading":{"tag":"盘后","latestPrice":6.99,"preClose":6.99,"latestTime":"16:05 EDT","volume":23,"amount":160.77,"timestamp":1744920312165},"delay":0,"floatShares":5446509,"shares":18702413,"eps":-10.437743,"marketStatus":"Market Closed","change":0.29,"latestTime":"04-17 16:00:00 EDT","open":6.52,"high":7.31,"low":6.52,"amount":135039.7002,"amplitude":0.11791,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.437743,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":6.7,"postHourTrading":{"tag":"盘后","latestPrice":6.99,"preClose":6.99,"latestTime":"16:05 EDT","volume":23,"amount":160.77,"timestamp":1744920312165},"volumeRatio":0.1452943340841707},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":5446509,"roa":"-681.04%","roe":"--","lyrEps":-10.437743,"volumeRatio":0.1452943340841707,"shares":18702413,"dividePrice":0,"high":7.31,"amplitude":0.11791,"preClose":6.7,"low":6.52,"week52Low":5.865,"pbRate":"-1.35","week52High":24.15,"institutionHeld":0,"latestPrice":6.99,"eps":-10.437743,"divideRate":0,"volume":19203,"delay":0,"ttmEps":-10.437743,"open":6.52,"prevYearClose":9.66,"prevWeekClose":7.23,"prevMonthClose":8.03,"prevQuarterClose":8.03,"fiveDayClose":7.31,"twentyDayClose":11.4,"sixtyDayClose":9.2},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1900954228,"yearFounded":2019,"employeeNum":14,"address":"628 Middlefield Road,Palo Alto,California,United States","zipCode":"94301"},"stockCompanyDetail":{"websiteUrl":"http://www.allovir.com","stockEarnings":[{"period":"1week","weight":-0.0438},{"period":"1month","weight":-0.2875},{"period":"3month","weight":-0.2468},{"period":"6month","weight":-0.6069},{"period":"1year","weight":-0.5985},{"period":"ytd","weight":-0.2764}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.05141},{"month":2,"riseRate":0.8,"avgChangeRate":0.066777},{"month":3,"riseRate":0.2,"avgChangeRate":-0.236404},{"month":4,"riseRate":0.4,"avgChangeRate":-0.104038},{"month":5,"riseRate":0.25,"avgChangeRate":-0.027821},{"month":6,"riseRate":0.25,"avgChangeRate":-0.072525},{"month":7,"riseRate":0.5,"avgChangeRate":0.034661},{"month":8,"riseRate":0.8,"avgChangeRate":0.189154},{"month":9,"riseRate":0.6,"avgChangeRate":-0.014837},{"month":10,"riseRate":0.2,"avgChangeRate":-0.070906},{"month":11,"riseRate":0.6,"avgChangeRate":0.030408},{"month":12,"riseRate":0,"avgChangeRate":-0.295433}],"exchange":"NASDAQ","name":"Kalaris Therapeutics Inc.","nameEN":"Kalaris Therapeutics Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":{"directors":[{"name":"David Hallal","position":"Chief Executive Officer and Director"},{"name":"Vikas Sinha","position":"President, Chief Financial Officer and Director"},{"name":"Ansbert Gadicke","position":"Director"},{"name":"Diana Brainard","position":"Director"},{"name":"Jeffrey S. Bornstein","position":"Director"},{"name":"John Wilson","position":"Director"},{"name":"Juan Vera","position":"Director"},{"name":"Malcolm Brenner","position":"Director"},{"name":"Morana Jovan Embiricos","position":"Director"}],"executives":[{"name":"David Hallal","position":"Chief Executive Officer and Director"},{"name":"Vikas Sinha","position":"President, Chief Financial Officer and Director"},{"name":"Agustin Melian","position":"Chief Medical Officer"},{"name":"Ann Leen","position":"Chief Scientific Officer"},{"name":"Brett Hagen","position":"Chief Accounting Officer"},{"name":"Edward Miller","position":"General Counsel"},{"name":"Ercem Atillasoy","position":"Chief Regulatory and Safety Officer"},{"name":"Jeroen van Beek","position":"Chief Commercial Officer"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-07","symbol":"KLRS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-01-16","symbol":"KLRS","defaultRemindTime":1737037800000,"type":"split","dateTimestamp":1737003600000,"forFactor":23,"toFactor":1,"ratio":23},{"market":"US","date":"2024-11-12","symbol":"KLRS","fiscalQuarterEnding":"2024/09","expectedEps":-0.14,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.04},{"market":"US","date":"2024-08-09","symbol":"KLRS","fiscalQuarterEnding":"2024/06","expectedEps":-0.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-0.05},{"market":"US","date":"2024-05-13","symbol":"KLRS","fiscalQuarterEnding":"2024/03","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2025-04-17","current":-1.811647,"percent":0.882353,"low":-2.839148,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"high":-1.746752,"avg":-2.113287,"sd":0.282591,"marketCap":125306167},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167}],"updateTime":1745067945558}}}